echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Baiji Shenzhou and springworks therapeutics carry out global clinical cooperation to evaluate the targeted combination therapy of advanced solid tumor

    Baiji Shenzhou and springworks therapeutics carry out global clinical cooperation to evaluate the targeted combination therapy of advanced solid tumor

    • Last Update: 2018-09-07
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    September 6, 2018 / American news agency / -- Baiji Shenzhou (NASDAQ: bgne; Hong Kong stock exchange code: 06160), a biomedical company in the commercial stage, focuses on the development and commercialization of innovative molecular targeting and tumor immunodrugs for cancer treatment; springworks therapeutics It is a rare disease and tumor medicine company in clinical stage, focusing on finding and developing innovative treatment schemes for patients lacking treatment Baiji Shenzhou and springworks therapeutics announced today that they have reached a global clinical cooperation agreement to evaluate the safety, tolerance and preliminary efficacy of the combination therapy of lifirafenib (bgb-283), an RAF dimer inhibitor, and pd-0325901, an MEK inhibitor, in the study of springworks therapeutics, in patients with advanced solid tumors According to the terms of the agreement, Baiji Shenzhou will be responsible for phase 1b clinical research on advanced solid tumor patients with RAS, RAF mutation and other MAPK pathway abnormalities, which is expected to be carried out in the first quarter of 2019, and all the cost of clinical research and management responsibility will be shared equally by both parties As part of the collaboration, springworks will oversee fixed dose preparations Mr Ou Lei Qiang, founder, CEO and chairman of Baiji Shenzhou, said: "Baiji Shenzhou is committed to developing innovative drugs for cancer patients with limited or no treatment options We are pleased to work with springworks therapeutics to explore the potential benefits of this combination therapy for patients with ras mutations There are huge unmet medical needs in this group of patients " Saqib Islam, CEO of springworks therapeutics, said: "about a quarter of all cancer patients carry ras gene mutations, which makes it a very important area to develop new cancer treatment programs Although anti Ras treatment has been studied for decades, so far no treatment has been approved The combination therapy of MEK inhibitor and RAF dimer inhibitor has a strong scientific theoretical basis, and the current preclinical data have shown the potential advantages of this combination therapy We look forward to cooperating with Baiji Shenzhou on the basis of the existing preclinical data " About lifrafenib lifirafenib, a small molecular kinase inhibitor in development with the inhibitory activity of RAF monomer and dimer, was independently developed by scientists in Beijing, China Lifirafenib has shown antitumor activity in preclinical models, cancer patients with V600E BRAF mutation and non V600E BRAF mutation, patients with non-small cell lung cancer and patients with KRAS mutation endometrial cancer So far, more than 150 patients worldwide have taken liferafenib Pd-0325901 was initially discovered by Pfizer scientists that pd-0325901 is a MEK inhibitor and a key signaling protein for cell survival and proliferation In clinical biopsy, pd-0325901 showed the activity of blocking MEK phosphorylation, thus preventing cell growth and causing cell death The preclinical model showed that the inhibition of MEK and RAF had a significant synergistic effect in Ras mutant solid tumors The combination of pd-0325901 and lifirafenib is expected to overcome the feedback loop that hinders the development of Ras mutant solid tumor therapy by vertically inhibiting MAPK signal pathway In addition, springworks plans to launch the clinical phase 2B trial of pd-0325901 single drug in the treatment of plexiform neurofibroma subtype 1 in 2019 Springworks will also continue to evaluate new licensing and collaboration opportunities for its MEK project to complement existing clinical research and further fulfill its mission of developing new therapies for the treatment of the lack of population About Baiji Shenzhou, a global, commercial stage, R & D-based biotechnology company, focusing on the research and development of molecular targeting and immunotherapy for tumor At present, Baiji Shenzhou has more than 1300 employees in mainland China, the United States, Australia and Switzerland, and its research product line includes new oral small molecule and monoclonal antibody anti-cancer drugs At present, Baiji Shenzhou is also building a drug combination program for anti-cancer treatment, aiming to bring lasting and far-reaching impact on the life of cancer patients Under the authorization of Xinji company, Baiji Shenzhou sells Abraxane ® paclitaxel for injection (nano albumin particle binding type), refume ® (lenalidomide) and vedasha ® (azacytidine for injection) [i] in China About springworks therapeutics springworks therapeutics is a rare disease and tumor company in the clinical stage, which focuses on exploring and developing innovative treatment schemes for patients who lack treatment The company was founded in September 2017, with a round of financing of US $103 million, led by orbo capital, Bain Capital and Pfizer Springworks therapeutics has the right of Pfizer's four clinical treatment programs Its strategic model is to provide a new development way for the promising research and treatment through cooperation with patient groups, academic partners, investors and biopharmaceutical partners Nirogacestat, the leading candidate drug of springworks therapeutics, is a γ - secretase inhibitor It has been approved as an orphan drug in the United States for the treatment of desmoid tumors, a rare non metastatic tumor of connective tissue cells, which can cause serious morbidity, pain and loss of function in children and adults Pd-0325901, the company's MEK inhibitor, is in clinical research as a single drug therapy for type 1 neurofibroma cluster neurofibroma subtype This rare genetic disease is caused by NF1 gene mutation that leads to the growth of nervous system tumors The company's clinical candidates in the early stage of clinical development include the fatty acid amide hydrolase (FAAH) inhibitor (pf-04457845) for central nervous system diseases and the Gardos channel inhibitor senecapoc for blood diseases.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.